Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale

Conclusion:
The study confirms the better sexual acceptability profile of agomelatine (25 or 50 mg) in healthy men and women, compared to escitalopram.

Trial registration name:
Evaluation of the effect of agomelatine and escitalopram on emotions and motivation in healthy male and female volunteers.

Trial registration number:
ISRCTN75872983.

Source: Journal of Psychopharmacology - September 22, 2015 Category: Psychiatry Authors: Montejo, A. L., Deakin, J., Gaillard, R., Harmer, C., Meyniel, F., Jabourian, A., Gabriel, C., Gruget, C., Klinge, C., MacFayden, C., Milligan, H., Mullings, E., Goodwin, G. Tags: Original Papers Source Type: research